<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166582">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02016898</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048136</org_study_id>
    <nct_id>NCT02016898</nct_id>
  </id_info>
  <brief_title>The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device</brief_title>
  <official_title>The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary focus of this study is to assess intraocular pressure and complication rates
      between patients who receive mitomycin-C using a sponge versus no-sponge.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in complication rates</measure>
    <time_frame>post-operative day 1, week 2, week 4, month 2, month 3 and month 6</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess complication rates between patients who receive mitomycin-C using a sponge versus no-sponge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intraocular pressure</measure>
    <time_frame>post-operative day 1, week 2, week 4, month 2, month 3 and month 6</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess final intraocular pressure lowering between patients who receive mitomycin-C using a sponge versus no-sponge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Sponge placement of MMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No-sponge placement of MMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placement of the sponge</intervention_name>
    <arm_group_label>Sponge placement of MMC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C</intervention_name>
    <arm_group_label>Sponge placement of MMC</arm_group_label>
    <arm_group_label>No-sponge placement of MMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women aged 18 years and older at screening.

          2. Diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, phakic or
             pseudophakic, with visual field or optic disc changes characteristic of glaucoma.

          3. Suitable candidate for trabeculectomy with Ex-PRESS glaucoma filtration device with
             MMC in the superonasal quadrant in the study eye which the physician deems as
             medically necessary.

          4. Capable and willing to provide consent

        Exclusion Criteria:

          1. Unable or unwilling to provide consent

          2. Any previous ocular surgeries in the study eye preventing placement of the
             trabeculectomy with Ex-PRESS glaucoma filtration device with MMC in the superonasal
             quadrant

          3. Any previous glaucoma drainage devices in the study eye

          4. Any abnormality other than glaucoma in the study eye that could affect applanation
             tonometry.

          5. Presence or history of any abnormality or disorder that could interfere with the
             study procedure or prevent the successful completion of the study.

          6. Presence or history of uveitis within 10 years or any other ocular infection or
             inflammation within 14 days before day 1.

          7. Any significant unstable cardiovascular, hepatic, renal, respiratory,
             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or
             psychiatric disease.

          8. Known Pregnancy or Breastfeeding

             Physical and Laboratory Findings

          9. Conjunctival scarring precluding a superonasal implantation location.

         10. Vitreous in the anterior chamber.

         11. Abnormality preventing reliable applanation tonometry in the study eye.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leon Herndon, MD</last_name>
      <phone>919-684-6622</phone>
      <email>hernd012@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Leon Herndon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>mitomycin-C</keyword>
  <keyword>express mini-shunt</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
